Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director · CEO and President | March 20, 2017 | March 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spyre Therapeutics, Inc.
Report date March 20, 2017 · Filed March 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2027-03-19 | Direct | 160,000 |
Reported balance
After 2017-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-20 · Grant · Acquired 160,000 · Balance 160,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2017 Filed Mar 22, 2017 16:53 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001140361-17-012947 · doc1.xml · derivative · entry 1 Lowe David George · CIK 0001392094 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2027-03-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.